Ivey Business School (Canada)
-
Pfizer and the Challenges of the Pharmaceutical Industry (A)
Renate Kratochvil; Phillip C. NellCase IVEY-9B19M076-EStrategyIn 2018, President of the United States, Donald Trump, criticized the company Pfizer Inc. (Pfizer) for increasing drug prices—which had been a strategic move by Pfizer in response to industry-wide challenges. This announcement highlighted the complex dynaStarting at €8.20
-
Sy.Med Development, Inc.
Randle RaggioCase IVEY-9B09A010-EEntrepreneurship, MarketingIn March of 2001, the president of Sy.Med Development, Inc. (Sy.Med), a small health-care software firm, was concerned about his company's sales performance in the year-to-date. Nine units were projected, but only three had been sold. As a result, Sy.Med was 66 per cent below the president's unit forecast, 210 per cent below his net income forecast, and had lost $40,000. The president wondered whether a change to the base price of the software wa...Starting at €8.20
-
Michael Shaps Winery: Evaluating the Custom Crush Opportunity
Randle Raggio; Ben EubanksCase IVEY-9B13A027-EEntrepreneurship, MarketingBy 2010, Virginia had become the fifth-largest wine-producing state in the United States and Michael Shaps had developed a reputation as one of Virginia’s premier winemakers. He had recently doubled his annual production capacity and was considering whether to increase production of his own “Michael Shaps”-label wines (MS), or accept offers to produce private-label wines (PL) for customers — a service he dubbed “custom crush.” He could increase h...Starting at €8.20
-
Pfizer and the Challenges of the Pharmaceutical Industry (B)
Renate Kratochvil; Phillip C. NellCase IVEY-9B19M077-EStrategyCase B complements Case A, describing pharmaceutical companies’ strategic responses—such as mega-mergers and acquisitions and specialization—to industry-wide global challenges and highlights strategic decisions by Pfizer’s chief executive officers betweenStarting at €5.74